Today: 30 April 2026
Browse Category

NYSE:BSX 15 January 2026 - 22 April 2026

US Stock Market Today: Nasdaq Leads Wall Street Rally as Iran Ceasefire Relief Meets Earnings Momentum

US Stock Market Today: Nasdaq Leads Wall Street Rally as Iran Ceasefire Relief Meets Earnings Momentum

The Nasdaq rose 1.29% as technology and chip stocks led gains after President Trump extended the Iran ceasefire. GE Vernova, Boeing, and Boston Scientific advanced following earnings reports. Oil hovered near $100, with fresh ship seizures in the Strait of Hormuz highlighting ongoing risks. At 11:25 a.m. ET, the Dow was up 381 points, the S&P 500 gained 61 points, and the Nasdaq climbed 314 points.
22 April 2026
······
Boston Scientific stock price slips again after earnings shock as BSX investors eye heart-rhythm sales

Boston Scientific stock price slips again after earnings shock as BSX investors eye heart-rhythm sales

Boston Scientific shares closed down 1.8% at $76.27 Friday, near post-earnings lows after a 17% plunge Wednesday on weak electrophysiology sales and a softer 2026 outlook. Trading volume reached 34.9 million shares. The stock lagged peers as the S&P 500 rose about 2%. Investors are watching early-quarter demand signals ahead of the next earnings update in late April.
7 February 2026
··
Boston Scientific stock rebounds after earnings shock as analysts cut targets on EP worries

Boston Scientific stock rebounds after earnings shock as analysts cut targets on EP worries

Boston Scientific shares rose 2.8% to $77.64 in Thursday’s after-hours trading, rebounding after a record 17% plunge Wednesday on weak Q4 electrophysiology and Watchman sales. Citi and Wells Fargo lowered price targets but kept positive ratings. Fourth-quarter net sales reached $5.29 billion, with adjusted EPS of $0.80. The company expects 2026 adjusted EPS of $3.43–$3.49.
6 February 2026
··
Boston Scientific stock tries to steady after an 18% earnings drop put EP business on edge

Boston Scientific stock tries to steady after an 18% earnings drop put EP business on edge

Boston Scientific shares rose about 1% in Thursday premarket trading after plunging 17.6% Wednesday on weak electrophysiology sales and a softer 2026 outlook. Q4 electrophysiology revenue missed analyst estimates, and U.S. Watchman sales fell short. The stock traded near $76.30 after closing at $75.50. CEO Michael Mahoney said Q4 results beat internal targets but warned of challenges in the first quarter.
5 February 2026
··
Boston Scientific (BSX) stock dives on electrophysiology sales miss — what to watch after the bell

Boston Scientific (BSX) stock dives on electrophysiology sales miss — what to watch after the bell

Boston Scientific shares fell nearly 18% in after-hours trading Wednesday after the company reported disappointing electrophysiology sales and lowered its 2026 growth outlook. U.S. demand for the Watchman implant also missed expectations. The company guided first-quarter adjusted EPS to $0.78–$0.80 and organic revenue growth of 8.5%–10%. Analysts are watching for further estimate cuts and commentary on heart-rhythm procedure trends.
4 February 2026
·
Boston Scientific stock price skids as key heart-rhythm sales miss jolts BSX

Boston Scientific stock price skids as key heart-rhythm sales miss jolts BSX

Boston Scientific shares fell 15% to $77.83 after quarterly electrophysiology sales missed Wall Street estimates, with Q4 revenue in that segment at $890 million versus a $933 million consensus. Analysts flagged fresh doubts about growth in electrophysiology and Watchman devices. The stock’s drop marked its sharpest one-day decline in over 25 years. Investors await Watchman “CHAMPION” trial data at the ACC.26 meeting in March.
4 February 2026
·
Boston Scientific stock slips today: what to know before earnings and key Watchman trial data

Boston Scientific stock slips today: what to know before earnings and key Watchman trial data

Boston Scientific (BSX.N) slipped 0.7% to $91.20 in Tuesday afternoon trading, with about 10.4 million shares exchanged. CEO Michael F. Mahoney filed to potentially sell up to 160,901 shares valued at $15 million. The company reports fourth-quarter earnings Wednesday morning. Investors await late-March CHAMPION-AF trial results for the Watchman device.
3 February 2026
··
Boston Scientific stock price drops today: BSX slides as investors size up Feb. 4 earnings, Watchman trial date

Boston Scientific stock price drops today: BSX slides as investors size up Feb. 4 earnings, Watchman trial date

Boston Scientific shares fell 1.6% to $92.01 Monday, lagging sector peers as the S&P 500 rose. Investors are watching for the company’s Feb. 4 earnings call and the March 28 release of CHAMPION-AF trial results for its Watchman device. TD Cowen maintained a buy rating, citing potential upside if the trial data proves positive.
2 February 2026
··
Boston Scientific stock snaps a 4-day run — what to watch before Feb. 4 earnings

Boston Scientific stock snaps a 4-day run — what to watch before Feb. 4 earnings

Boston Scientific shares fell 1.6% to $92.33 Thursday, ending a four-day rally on heavy volume after the company completed its acquisition of Nalu Medical. The stock underperformed sector peers as investors awaited fourth-quarter results due Feb. 4 and looked for updates on recent deal activity, including the $14.5 billion Penumbra purchase.
30 January 2026
······
ISRG stock slips after FDA clears da Vinci 5 for heart procedures; TD Cowen starts at Buy

ISRG stock slips after FDA clears da Vinci 5 for heart procedures; TD Cowen starts at Buy

Intuitive Surgical shares fell 0.7% to $525.09 Tuesday after the FDA cleared its da Vinci 5 robot for select cardiac procedures. The S&P 500 ETF rose 0.5% and QQQ gained 0.9%. TD Cowen initiated coverage with a Buy rating and $660 target, citing potential for expanded hospital adoption. Intuitive forecasts 13–15% da Vinci procedure growth in 2026, with a 1.2% revenue hit from tariffs.
27 January 2026
····
Boston Scientific stock (BSX) climbs as heart-rhythm rivalry and deal risk stay in play

Boston Scientific stock (BSX) climbs as heart-rhythm rivalry and deal risk stay in play

Boston Scientific shares rose about 1% to $92.20 Friday, outperforming a weaker healthcare sector as investors focused on pulsed-field ablation for atrial fibrillation. The company’s $14.5 billion deal to buy Penumbra and its upcoming Feb. 4 earnings report are drawing scrutiny. Johnson & Johnson posted $24.6 billion in quarterly sales and gave 2026 guidance, while Medtronic and Abbott shares fell.
23 January 2026
Boston Scientific (BSX) stock falls again as traders digest $14.5 billion Penumbra buy

Boston Scientific (BSX) stock falls again as traders digest $14.5 billion Penumbra buy

Boston Scientific shares fell 1.8% to $88.44 Friday after its $14.5 billion deal to buy Penumbra, while Penumbra rose 0.3% to $351.62. Boston will fund most of the purchase with cash and new debt, expecting a $0.06–$0.08 hit to adjusted EPS in the first year. Penumbra shareholders can choose cash or Boston stock. Deal filings and Boston’s earnings call are set for February 4.
16 January 2026
··
Boston Scientific (BSX) stock drops after $14.5B Penumbra deal; FDA nod and earnings date ahead

Boston Scientific (BSX) stock drops after $14.5B Penumbra deal; FDA nod and earnings date ahead

Boston Scientific shares fell 4% Thursday after it announced a $14.5 billion cash-and-stock deal to buy Penumbra at $374 per share. Penumbra stock jumped 12% to $350.49. Boston Scientific warned of near-term EPS dilution and will fund about $11 billion in cash using debt and existing funds. Investors are watching for more details ahead of Boston Scientific’s earnings report on Feb. 4.
16 January 2026
···
Penumbra stock pops after Boston Scientific’s $14.5 billion buyout — what PEN investors watch next

Penumbra stock pops after Boston Scientific’s $14.5 billion buyout — what PEN investors watch next

Penumbra shares jumped 11.8% to $350.49 in after-hours trading Thursday after Boston Scientific announced a $14.5 billion cash-and-stock acquisition valuing Penumbra at $374 per share. The deal requires Penumbra shareholder approval and antitrust clearance. Penumbra posted preliminary Q4 revenue growth of over 21% year-over-year. Traders focused on the deal spread and closing risks.
15 January 2026
··
1 2

Stock Market Today

  • ASX set to slide as oil prices jump over $120 a barrel
    April 29, 2026, 6:07 PM EDT. The Australian share market (ASX) is expected to open lower, with futures down 0.8% to 8,627 points, following mixed results on Wall Street. The Dow Jones fell 0.6%, S&P 500 slipped 0.04%, while the Nasdaq rose 0.6%. European markets also declined, led by the FTSE down 1.2%. Oil prices surged 8.7% to over $US120 a barrel, driven by Brent crude hitting $US120.92. Commodities like iron ore rose 0.6%, while precious metals and the Australian dollar weakened. This sharp oil price increase pressures markets and is a key factor behind the ASX's anticipated drop. The market will be closely watching further economic and commodity developments throughout the trading day.

Latest article

Qualcomm Stock Jumps After Q2 Earnings Beat: Why a Weak Forecast Didn’t Stop the Rally

Qualcomm Stock Jumps After Q2 Earnings Beat: Why a Weak Forecast Didn’t Stop the Rally

30 April 2026
Qualcomm shares jumped late Wednesday after the company beat adjusted profit forecasts and said China’s smartphone slump may be ending, despite a weak third-quarter outlook. Fiscal Q2 revenue fell 3% to $10.6 billion; adjusted EPS reached $2.65, topping estimates. Handset chip sales dropped 13%, while automotive and IoT revenue climbed. Qualcomm expects Q3 revenue below Wall Street targets due to memory supply issues.
Microsoft Stock Falls After Earnings Beat as Azure Growth Hits 40% and AI Revenue Surges

Microsoft Stock Falls After Earnings Beat as Azure Growth Hits 40% and AI Revenue Surges

29 April 2026
Microsoft reported fiscal Q3 revenue of $82.9 billion, up 18%, and net income of $31.8 billion, up 23%, beating analyst estimates. Azure revenue jumped 40%, and AI business annual run rate hit $37 billion, up 123%. Shares fell over 2% after hours as investors focused on rising capital expenditures, which climbed 49% to $31.9 billion. Free cash flow dropped to $15.8 billion from $20.3 billion a year earlier.
Meta Stock Slides as $145 Billion AI Spending Plan Overshadows Blowout Earnings

Meta Stock Slides as $145 Billion AI Spending Plan Overshadows Blowout Earnings

29 April 2026
Meta Platforms shares dropped about 5% in after-hours trading Wednesday after the company raised its 2026 capital spending forecast to $125–$145 billion. First-quarter revenue rose 33% to $56.31 billion, beating estimates, while net income reached $26.77 billion, boosted by an $8.03 billion tax benefit. Meta expects second-quarter revenue of $58–$61 billion. Daily active users across its apps increased 4% to 3.56 billion.
Go toTop